Back to search results

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Abroad (travel likely)RecruitingPHASE1

Conditions

Pancreatic Ductal Adenocarcinoma · Borderline Resectable Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma · Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

    Contact: Study coordinator (Patrice Jones) · Patrice.Jones@hoag.org · 949-764-5501
    Contact: Principal Investigator (Tara Seery, MD)

  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Eliza Beal, MD) · beale@karmanos.org · 800-KARMANOS
    Contact: Principal Investigator (Eliza Beal, MD)

  • Northwell Health Zuckerberg Cancer Center, Lake Success, New York, United States

    Contact: Study coordinator (Jenna Battaglia) · JBattaglia2@northwell.edu · 516-734-8812
    Contact: Principal Investigator (Danielle Deperalta, MD)

  • University of Texas Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Emilia Callahan) · emilia.callahan@utsouthwestern.edu · 214-648-5870
    Contact: Principal Investigator (Matthew Porembka, MD)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Ching-Wei Tzeng, MD) · cdtzeng@mdanderson.org · 713-792-0386
    Contact: Principal Investigator (Ching-Wei Tzeng, MD)

  • Virginia Mason Medical Center, Seattle, Washington, United States

    Contact: Study coordinator (Colette Treperinas) · Colette.Treperinas@commonspirit.org · 206-287-6286
    Contact: Principal Investigator (Vincent Picozzi, MD)
View source on ClinicalTrials.gov(opens in a new tab)